Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (6817)	7/27/1998 4:23:00 PM
From: opalapril	Read Replies (3) \| Respond to of 17367

Market predictions plucked out of thin air or coaxed from charts hold interest for some, perhaps; but who among us has ever seen Xoma affected by macro market trends? The company paddles its own canoe on its own lake unhindered (and, correspondingly, not helped) by broader market currents. For me the whole ship sails or sinks with the P-3 results. All the rest is just inconsequential wind. I am sufficiently persuaded by the earlier safety study and all the rBPI research retold here that if Neuprex works I think there's a very good chance of a halt in September. If there is no early halt, I for one will conclude the efficacy issue remains too close to call. In that event I'll probably bail out and maybe even join the skeptics. This has not been a pleasant investment experience, George and Robert and the rest of you good heads on SI notwithstanding.